Type of Hodgkin's lymphoma-Classical Hodgkin's lymphma Posts on Medivizor

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

$Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.$

Posted by Medivizor on Jun 11, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) before stem cell transplantation. The data showed that pembrolizumab was effective and safe with manageable side effects in these patients. Some background...

Comparing the health-related quality of life outcomes between pembrolizumab and brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.

$Comparing the health-related quality of life outcomes between pembrolizumab and brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.$

Posted by Medivizor on Dec 5, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the health-related quality of life (HR-QoL) outcomes between pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab improved the HR-QoL outcomes compared to BV in these patients. Some...

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Posted by Medivizor on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...

Evaluating the clinical outcomes in patients with relapsed or refractory classical Hodgkin lymphoma after first-line treatment.

$Evaluating the clinical outcomes in patients with relapsed or refractory classical Hodgkin lymphoma after first-line treatment.$

Posted by Medivizor on Oct 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the characteristics, treatment patterns, and outcomes of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (HL) after treatment with first-line therapy. Some background HL is a cancer of white blood cells. Most patients with HL respond to first-line chemotherapy regimens. However, up to...

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Posted by Medivizor on Jun 13, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapse (HRR) classical Hodgkin’s lymphoma (cHL). The authors concluded that the outcomes of patients with HRR cHL have improved over the last 15 years with...

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Posted by Medivizor on Jun 6, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Posted by Medivizor on May 23, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of incorporating brentuximab vedotin (BV; Adcetris) as a substitution for vincristine in the OEPA (vincristine, etoposide, prednisone, doxorubicin) or COPD (cyclophosphamide, vincristine, prednisone, dacarbazine) chemotherapy regimen in children with high-risk classical...

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

$Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?$

Posted by Medivizor on May 15, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors assessed the effectiveness of autologous stem cell transplantation (ASCT) after anti-PD-1 therapy for the treatment of patients with high-risk relapsed/refractory (r/r) Hodgkin lymphoma (HL). The study found that ASCT after anti-PD-1 therapy had very good outcomes in patients with r/r HL. Some background Standard...

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

$Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma$

Posted by Medivizor on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of the BGD (bendamustine, gemcitabine, and dexamethasone) regimen in patients with previously treated Hodgkin lymphoma (HL). This study concluded that BGD is well-tolerated and highly effective in these patients. Some background Hodgkin lymphoma (HL) is a cancer that...

Relapsed or refractory Hodgkin lymphoma: how does stopping and restarting nivolumab impact patient outcomes?

$Relapsed or refractory Hodgkin lymphoma: how does stopping and restarting nivolumab impact patient outcomes?$

Posted by Medivizor on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of stopping and restarting nivolumab (Opdivo) in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The authors concluded that nivolumab retreatment is well tolerated and effective in patients who achieved complete response (CR; complete...

Brentuximab vedotin plus nivolumab in older or chemotherapy-ineligible patients with Hodgkin lymphoma

Posted by Medivizor on Nov 15, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of brentuximab vedotin (BV; Adcetris) and nivolumab (Opdivo) in older patients with Hodgkin lymphoma (HL) or younger patients unsuitable for standard treatment. This study concluded that this treatment may benefit these...

Pembrolizumab followed by AVD treatment in newly diagnosed advanced classical Hodgkin lymphoma

Posted by Medivizor on Oct 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of pembrolizumab (Keytruda) followed by AVD (doxorubicin, vinblastine, and dacarbazine) treatment in patients with high-risk classical Hodgkin lymphoma. This study concluded that this treatment was safe and effective in these patients. Some...

« Older Entries

Type of Hodgkin’s lymphoma-Classical Hodgkin’s lymphma Posts on Medivizor

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

Comparing the health-related quality of life outcomes between pembrolizumab and brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Evaluating the clinical outcomes in patients with relapsed or refractory classical Hodgkin lymphoma after first-line treatment.

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

Relapsed or refractory Hodgkin lymphoma: how does stopping and restarting nivolumab impact patient outcomes?

Brentuximab vedotin plus nivolumab in older or chemotherapy-ineligible patients with Hodgkin lymphoma

Pembrolizumab followed by AVD treatment in newly diagnosed advanced classical Hodgkin lymphoma

Categories

Recent Posts

Archives

Type of Hodgkin’s lymphoma-Classical Hodgkin’s lymphma Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email